The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase1, randomized, double- blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamies of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.
